July 21, 2022 02:50 PM EDT

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

Zachary Brennan

Senior Editor

The battle over whether Biogen’s Alzheimer’s drug Aduhelm actually helps patients may never end, but in a recent SEC filing, Biogen, at least for accounting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

Zachary Brennan

Senior Editor

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Exclusive: Florida cancer biotech raises $100M Series A

For ac­count­ing pur­pos­es, Bio­gen says its $223M in­ven­to­ry of Aduhelm is ba­si­cal­ly worth­less

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Exclusive: Florida cancer biotech raises $100M Series A